 |
||||||||||
|
||||||||||
|
|
||||||||||
|
||||||||||
|
 |
DLS Home |
|
Programs & Research |
|
DLS Branches |
|
Publications & Products |
|
Training Opportunities |
|
Employment |
|
Contact Us |
|
National Report on Human Exposure to Environmental Chemicals |
|
National Report on Biochemical Indicators of Diet and Nutrition |
|
Newborn Screening Laboratory Bulletin |
|
DLS Brochure |
GENETICS
DNA Bank
Using specimens from participants in CDC's National Health and Nutrition Examination Survey (NHANES), CDC's Environmental Health Laboratory has established a unique, population-based DNA bank for studying gene-environment interactions and genetic risk factors for diseases, such as iron overload disease (hemochromatosis) or kidney disease among people with diabetes. The DNA is preserved in a manner that will allow thousands of genetic tests to be done on the DNA from a single sample. The laboratory is working with CDC's National Center for Health Statistics to make the bank available to researchers.
Genetics of Kidney in Diabetes Study
In the United States, about a million people, most of them children, have a disease known as Type 1 diabetes. CDC's Environmental Health Laboratory is establishing a collection of DNA, serum, plasma, and urine for studying the genetic risk factors of the renal disease of Type 1 diabetes. The Genetics of Kidney in Diabetes (GoKinD) Study is designed to be part of an international effort to provide sample sets for the study of the genes predisposing to renal disease. GoKinD is a collaboration between CDC, the Juvenile Diabetes Research Foundation (JDRF), Joslin Diabetes Center, the George Washington University Biostatistics Department and the University of Minnesota. This study will provide a sample collection from families with Type 1 diabetes and kidney disease together with samples from control subjects who have Type 1 diabetes but no kidney disease. This collection will help determine pathways for intervention to prevent diabetic kidney disease and allow targeting of preventive therapies.
Diabetes Autoantibody Standardization Program
Diabetes is an autoimmune disease, which means that the body attacks itself and destroys the cells that make insulin in an organ called the pancreas. People with Type 1 diabetes have to take insulin for the rest of their lives. They are also at higher risk for problems such as blindness, nerve damage, kidney failure, stroke, and heart attack than are people who do not have diabetes. Biochemical analyses of autoantibodies that destroy the cells that produce insulin are crucial for predicting which people have the greatest risk of developing Type 1 diabetes. These analyses provide the most sensitive and meaningful measures for accurately targeting program interventions and, thus, are central to efforts to prevent and delay the onset of this disease. Laboratories throughout the world measure these autoantibodies, but the results vary from laboratory to laboratory. Accurate autoantibody measurements are necessary for the identification of those at risk. Working with the Immunology of Diabetes Society, in 2000 CDC's Environmental Health Laboratory established the Diabetes Autoantibody Standardization Program (DASP) to improve autoantibody measurements worldwide. Currently, 47 key laboratories from 17 countries participate in DASP.
For More Information...
DLS Resources
CDC Resources
U.S. Federal Government Resources
Non-Federal Resources
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
